Evaluation of anti-IgE antibody therapy in the patients with wheat allergy
Not Applicable
Completed
- Conditions
- Wheat allergy
- Registration Number
- JPRN-UMIN000014272
- Lead Sponsor
- Shimane University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had been administrated of Omalizumab in history, and patients who receive immunosuppressive drugs.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the sensitization status before and after the therapy using basophil activation test, specific IgE test, and enzyme-linked immunosorbent assay.
- Secondary Outcome Measures
Name Time Method Food challenge test before and after the treatment if available.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie anti-IgE antibody therapy efficacy in wheat allergy (JPRN-UMIN000014272)?
How does anti-IgE therapy compare to standard-of-care (e.g., epinephrine/antihistamines) in wheat allergy treatment outcomes?
Which biomarkers predict response to anti-IgE therapy in wheat allergy clinical trials (JPRN-UMIN000014272)?
What adverse events are reported in JPRN-UMIN000014272 anti-IgE antibody therapy for wheat allergy?
Are there combination therapies with anti-IgE antibodies and other biologics for wheat allergy treatment?